The rise of GLP-1s to improve metabolic health

As America confronts its obesity epidemic, plan members and providers alike have turned to glucagon-like peptide-1 receptor agonists (GLP-1s) for their significant weight loss results. Our new white paper provides a clinical backdrop for the success of this dynamic drug class. We explore the mounting demand for these drugs, how they work and what they cost, advancing health equity, and other key considerations for plan sponsors.